21.01.2025 14:51:27
|
Crown Laboratories, Revance Amend A&R Merger Agreement; Increases Offer Price To $3.65/shr
(RTTNews) - Crown Laboratories and Revance Therapeutics (RVNC) announced that, on January 17, 2025, they amended their previously announced Amended and Restated Merger Agreement. Revance's stockholders will receive $3.65 per share of common stock, par value $0.001 per share in cash, without interest and less any applicable tax withholding, representing $0.55 or 17% per share more than the prior offer price.
Crown will extend its existing tender offer for all of Revance's outstanding Shares until one minute past 11:59 p.m., Eastern Time, on February 4, 2025.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Revance Therapeutics Incmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Revance Therapeutics Incmehr Analysen
Aktien in diesem Artikel
Revance Therapeutics Inc | 3,44 | -31,20% |
|